Talus Bio is a drug discovery biotech company that develops drugs targeting undruggable transcription factors using AI.
Talus Bio has raised $11.2M in total funding. The most recent round was Seed. The last funding was announced in September 2026.
Talus Bio's investors include Y Combinator, Fifty Years, NFX, National Science Foundation, Pioneer Fund.
Talus Bio is headquartered in Seattle, United States.
Talus Bio is a drug discovery biotech company that develops drugs targeting undruggable transcription factors using AI.
Talus Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Talus Bio — Funding & Investors." VCBacked, September 21, 2026, https://www.vcbacked.co/company/talus-bio. Accessed October 17, 2026.
VCBacked. (2026). Talus Bio — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/talus-bio
{{cite web |title=Talus Bio — Funding & Investors |url=https://www.vcbacked.co/company/talus-bio |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated